Advertisement

Senataxin, A Novel Helicase at the Interface of RNA Transcriptome Regulation and Neurobiology: From Normal Function to Pathological Roles in Motor Neuron Disease and Cerebellar Degeneration

  • Craig L. Bennett
  • Albert R. La Spada
Part of the Advances in Neurobiology book series (NEUROBIOL, volume 20)

Abstract

Senataxin (SETX) is a DNA-RNA helicase whose C-terminal region shows homology to the helicase domain of the yeast protein Sen1p. Genetic discoveries have established the importance of SETX for neural function, as recessive mutations in the SETX gene cause Ataxia with Oculomotor Apraxia type 2 (AOA2) (OMIM: 606002), which is the third most common form of recessive ataxia, after Friedreich’s ataxia and Ataxia-Telangiectasia. In addition, rare, dominant SETX mutations cause a juvenile-onset form of Amyotrophic Lateral Sclerosis (ALS), known as ALS4. SETX performs a number of RNA regulatory functions, including maintaining RNA transcriptome homeostasis. Over the last decade, altered RNA regulation and aberrant RNA-binding protein function have emerged as a central theme in motor neuron disease pathogenesis, with evidence suggesting that sporadic ALS disease pathology may overlap with the molecular pathology uncovered in familial ALS. Like other RNA processing proteins linked to ALS, the basis for SETX gain-of-function motor neuron toxicity remains ill-defined. Studies of yeast Sen1p and mammalian SETX protein have revealed a range of important RNA regulatory functions, including resolution of R-loops to permit transcription termination, and RNA splicing. Growing evidence suggests that SETX may represent an important genetic modifier locus for sporadic ALS. In cycling cells, SETX is found at nuclear foci during the S/G2 cell-cycle transition phase, and may function at sites of collision between components of the replisome and transcription machinery. While we do not yet know which SETX activities are most critical to neurodegeneration, our evolving understanding of SETX function will undoubtedly be crucial for not only understanding the role of SETX in ALS and ataxia disease pathogenesis, but also for delineating the mechanistic biology of fundamentally important molecular processes in the cell.

Keywords

Senataxin Helicase R-Loops Nuclear exosome RENT1 IGHMBP2 Sen1p Exosc9 Sumo Nucleolus tRNA 

Notes

Acknowledgments

Our SETX research is supported by a grant from the Robert Packard Center for ALS Research at the Johns Hopkins School of Medicine.

References

  1. 1.
    Le Ber I, et al. Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. Brain. 2004;127:759–67.CrossRefPubMedGoogle Scholar
  2. 2.
    Rabin BA, et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain. 1999;122:1539–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Cady J, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015;77:100–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen YZ, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74:1128–35.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Moreira MC, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet. 2004;36:225–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Padmanabhan K, Robles MS, Westerling T, Weitz CJ. Feedback regulation of transcriptional termination by the mammalian circadian clock PERIOD complex. Science. 2012;337:599–602.CrossRefPubMedGoogle Scholar
  7. 7.
    Yuce O, West SC. Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response. Mol Cell Biol. 2013;33:406–17.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ursic D, Chinchilla K, Finkel JS, Culbertson MR. Multiple protein/protein and protein/RNA interactions suggest roles for yeast DNA/RNA helicase Sen1p in transcription, transcription-coupled DNA repair and RNA processing. Nucleic Acids Res. 2004;32:2441–52.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lupski JR. Charcot-Marie-tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity. Pediatr Res. 1999;45:159–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Warner LE, Roa BB, Lupski JR. Absence of PMP22 coding region mutations in CMT1A duplication patients: further evidence supporting gene dosage as a mechanism for Charcot-Marie-Tooth disease type 1A. Hum Mutat. 1996;8:362.CrossRefPubMedGoogle Scholar
  11. 11.
    Nihei Y, Ito D, Suzuki N. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS). J Biol Chem. 2012;287:41310–23.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kim HD, Choe J, Seo YS. The sen1(+) gene of Schizosaccharomyces pombe, a homologue of budding yeast SEN1, encodes an RNA and DNA helicase. Biochemistry. 1999;38:14697–710.CrossRefPubMedGoogle Scholar
  13. 13.
    Ghaemmaghami S, et al. Global analysis of protein expression in yeast. Nature. 2003;425:737–41.CrossRefPubMedGoogle Scholar
  14. 14.
    Borggrefe T, Davis R, Bareket-Samish A, Kornberg RD. Quantitation of the RNA polymerase II transcription machinery in yeast. J Biol Chem. 2001;276:47150–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Svejstrup JQ, et al. Evidence for a mediator cycle at the initiation of transcription. Proc Natl Acad Sci U S A. 1997;94:6075–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Beck M, et al. The quantitative proteome of a human cell line. Mol Syst Biol. 2011;7:549.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Avemaria F, et al. Mutation in the senataxin gene found in a patient affected by familial ALS with juvenile onset and slow progression. Amyotroph Lateral Scler. 2011;12:228–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Rudnik-Schoneborn S, Arning L, Epplen JT, Zerres K. SETX gene mutation in a family diagnosed autosomal dominant proximal spinal muscular atrophy. Neuromuscul Disord. 2012;22:258–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Anheim M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009;132:2688–98.CrossRefGoogle Scholar
  20. 20.
    Suraweera A, et al. Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage. J Cell Biol. 2007;177:969–79.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vantaggiato C, et al. Novel SETX variants in a patient with ataxia, neuropathy, and oculomotor apraxia are associated with normal sensitivity to oxidative DNA damaging agents. Brain Dev. 2014;36:682–9.CrossRefPubMedGoogle Scholar
  22. 22.
    De Amicis A, et al. Role of senataxin in DNA damage and telomeric stability. DNA Repair. 2011;10:199–209.CrossRefPubMedGoogle Scholar
  23. 23.
    Lynch DR, Braastad CD, Nagan N. Ovarian failure in ataxia with oculomotor apraxia type 2. Am J Med Genet A. 2007;143:1775–7.CrossRefGoogle Scholar
  24. 24.
    Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–11.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bennett CL, La Spada AR. Unwinding the role of senataxin in neurodegeneration. Discov Med. 2015;19:127–36.PubMedGoogle Scholar
  26. 26.
    Weng Y, Czaplinski K, Peltz SW. Genetic and biochemical characterization of mutations in the ATPase and helicase regions of the Upf1 protein. Mol Cell Biol. 1996;16:5477–90.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Medghalchi SM, et al. Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential for mammalian embryonic viability. Hum Mol Genet. 2001;10:99–105.CrossRefPubMedGoogle Scholar
  28. 28.
    Barmada SJ, et al. Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc Natl Acad Sci U S A. 2015;112:7821–6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Grohmann K, et al. Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat Genet. 2001;29:75–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Lefebvre S, Burglen L, Frezal J, Munnich A, Melki J. The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet. 1998;7:1531–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Cox GA, Mahaffey CL, Frankel WN. Identification of the mouse neuromuscular degeneration gene and mapping of a second site suppressor allele. Neuron. 1998;21:1327–37.CrossRefPubMedGoogle Scholar
  32. 32.
    Ursic D, DeMarini DJ, Culbertson MR. Inactivation of the yeast Sen1 protein affects the localization of nucleolar proteins. Mol Gen Genet. 1995;249:571–84.CrossRefPubMedGoogle Scholar
  33. 33.
    Ursic D, Himmel KL, Gurley KA, Webb F, Culbertson MR. The yeast SEN1 gene is required for the processing of diverse RNA classes. Nucleic Acids Res. 1997;25:4778–85.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Winey M, Culbertson MR. Mutations affecting the tRNA-splicing endonuclease activity of Saccharomyces cerevisiae. Genetics. 1988;118:609–17.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Rasmussen TP, Culbertson MR. The putative nucleic acid helicase Sen1p is required for formation and stability of termini and for maximal rates of synthesis and levels of accumulation of small nucleolar RNAs in Saccharomyces cerevisiae. Mol Cell Biol. 1998;18:6885–96.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Steinmetz EJ, Conrad NK, Brow DA, Corden JL. RNA-binding protein Nrd1 directs poly(A)-independent 3′-end formation of RNA polymerase II transcripts. Nature. 2001;413:327–31.CrossRefPubMedGoogle Scholar
  37. 37.
    Steinmetz EJ, Brow DA. Repression of gene expression by an exogenous sequence element acting in concert with a heterogeneous nuclear ribonucleoprotein-like protein, Nrd1, and the putative helicase Sen1. Mol Cell Biol. 1996;16:6993–7003.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Rondon AG, Mischo HE, Kawauchi J, Proudfoot NJ. Fail-safe transcriptional termination for protein-coding genes in S. cerevisiae. Mol Cell. 2009;36:88–98.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Steinmetz EJ, et al. Genome-wide distribution of yeast RNA polymerase II and its control by Sen1 helicase. Mol Cell. 2006;24:735–46.CrossRefPubMedGoogle Scholar
  40. 40.
    Reynolds JJ, Stewart GS. A single strand that links multiple neuropathologies in human disease. Brain. 2013;136:14–27.CrossRefPubMedGoogle Scholar
  41. 41.
    Skourti-Stathaki K, Proudfoot NJ, Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol Cell. 2011;42:794–805.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Banerjee A, Sammarco MC, Ditch S, Wang J, Grabczyk E. A novel tandem reporter quantifies RNA polymerase II termination in mammalian cells. PLoS One. 2009;4:e6193.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Becherel OJ, et al. Senataxin plays an essential role with DNA damage response proteins in meiotic recombination and gene silencing. PLoS Genet. 2013;9:e1003435.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Elson A, et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A. 1996;93:13084–9.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Yeo AJ, et al. R-loops in proliferating cells but not in the brain: implications for AOA2 and other autosomal recessive ataxias. PLoS One. 2014;9:e90219.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Han Z, Libri D, Porrua O. Biochemical characterization of the helicase Sen1 provides new insights into the mechanisms of non-coding transcription termination. Nucleic Acids Res. 2017;45:1355–70.CrossRefPubMedGoogle Scholar
  47. 47.
    Yu K, Chedin F, Hsieh CL, Wilson TE, Lieber MR. R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nat Immunol. 2003;4:442–51.CrossRefPubMedGoogle Scholar
  48. 48.
    Bennett CL, et al. Protein interaction analysis of senataxin and the ALS4 L389S mutant yields insights into senataxin post-translational modification and uncovers mutant-specific binding with a brain cytoplasmic RNA-encoded peptide. PLoS One. 2013;8:e78837.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Richard P, Feng S, Manley JL. A SUMO-dependent interaction between Senataxin and the exosome, disrupted in the neurodegenerative disease AOA2, targets the exosome to sites of transcription-induced DNA damage. Genes Dev. 2013;27:2227–32.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Suraweera A, et al. Functional role for senataxin, defective in ataxia oculomotor apraxia type 2, in transcriptional regulation. Hum Mol Genet. 2009;18:3384–96.CrossRefPubMedGoogle Scholar
  51. 51.
    Deng HX, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993;261:1047–51.CrossRefPubMedGoogle Scholar
  52. 52.
    DeMarini DJ, et al. The yeast SEN3 gene encodes a regulatory subunit of the 26S proteasome complex required for ubiquitin-dependent protein degradation in vivo. Mol Cell Biol. 1995;15:6311–21.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Carroll KL, Pradhan DA, Granek JA, Clarke ND, Corden JL. Identification of cis elements directing termination of yeast nonpolyadenylated snoRNA transcripts. Mol Cell Biol. 2004;24:6241–52.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Vasiljeva L, Buratowski S. Nrd1 interacts with the nuclear exosome for 3′ processing of RNA polymerase II transcripts. Mol Cell. 2006;21:239–48.CrossRefPubMedGoogle Scholar
  55. 55.
    Kuehner JN, Pearson EL, Moore C. Unravelling the means to an end: RNA polymerase II transcription termination. Nat Rev Mol Cell Biol. 2011;12:283–94.CrossRefPubMedGoogle Scholar
  56. 56.
    Richard P, Manley JL. Transcription termination by nuclear RNA polymerases. Genes Dev. 2009;23:1247–69.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Chen YZ, et al. Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol Dis. 2006;23:97–108.CrossRefPubMedGoogle Scholar
  58. 58.
    Roda RH, Rinaldi C, Singh R, Schindler AB, Blackstone C. Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage. J Clin Neurosci. 2014;21:1627–31.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Helmrich A, Ballarino M, Nudler E, Tora L. Transcription-replication encounters, consequences and genomic instability. Nat Struct Mol Biol. 2013;20:412–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Helmrich A, Ballarino M, Tora L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol Cell. 2011;44:966–77.CrossRefPubMedGoogle Scholar
  61. 61.
    Lukas C, et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol. 2011;13:243–53.CrossRefPubMedGoogle Scholar
  62. 62.
    de Planell-Saguer M, Schroeder DG, Rodicio MC, Cox GA, Mourelatos Z. Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery. Hum Mol Genet. 2009;18:2115–26.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Maddatu TP, Garvey SM, Schroeder DG, Hampton TG, Cox GA. Transgenic rescue of neurogenic atrophy in the nmd mouse reveals a role for Ighmbp2 in dilated cardiomyopathy. Hum Mol Genet. 2004;13:1105–15.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Hanada T, et al. CLP1 links tRNA metabolism to progressive motor-neuron loss. Nature. 2013;495:474–80.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Karaca E, et al. Human CLP1 mutations alter tRNA biogenesis, affecting both peripheral and central nervous system function. Cell. 2014;157:636–50.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Lee JW, et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature. 2006;443:50–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Ishimura R, et al. RNA function. Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration. Science. 2014;345:455–9.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Wan J, et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat Genet. 2012;44:704–8.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Erazo A, Goff SP. Nuclear matrix protein Matrin 3 is a regulator of ZAP-mediated retroviral restriction. Retrovirology. 2015;12:57.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet. 1999;8:1893–900.CrossRefPubMedGoogle Scholar
  71. 71.
    Li DK, Tisdale S, Lotti F, Pellizzoni L. SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin Cell Dev Biol. 2014;32:22–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650–5.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Cirulli ET, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436–41.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Couthouis J, Raphael AR, Daneshjou R, Gitler AD. Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. PLoS Genet. 2014;10:e1004704.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Kenna KP, et al. Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. J Med Genet. 2013;50:776–83.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyDuke University School of MedicineDurhamUSA
  2. 2.Department of NeurobiologyDuke University School of MedicineDurhamUSA
  3. 3.Department of Cell BiologyDuke University School of MedicineDurhamUSA
  4. 4.Duke Center for Neurodegeneration & NeurotherapeuticsDuke University School of MedicineDurhamUSA

Personalised recommendations